Ismail, Mohamed
Martin, Stephen R.
George, Roger
Houghton, Francesca
Kelly, Geoff
Chaleil, Raphaël A. G.
Anastasiou, Panayiotis
Wang, Xinyue
O’Reilly, Nicola
Federico, Stefania
Joshi, Dhira
Nagaraj, Hemavathi
Cooley, Rachel
Hui, Ning Sze
Molina-Arcas, Miriam
Hancock, David C.
Tavassoli, Ali
Downward, Julian
Funding for this research was provided by:
HORIZON EUROPE European Research Council (RASImmune)
HORIZON EUROPE European Research Council (RASImmune)
HORIZON EUROPE European Research Council (RASImmune)
HORIZON EUROPE European Research Council (RASImmune)
HORIZON EUROPE European Research Council (RASImmune)
HORIZON EUROPE European Research Council (RASImmune)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (A20185)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Cancer Research UK (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Wellcome Trust (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
Medical Research Council (FC001070)
The Francis Crick Institute
Article History
Received: 13 July 2022
Accepted: 24 January 2023
First Online: 2 February 2023
Change Date: 13 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-91151-4
Competing interests
: J.D. has acted as a consultant for AstraZeneca, Roche, Jubilant, Theras, BridgeBio, and Vividion and receives research funding from Bristol Myers Squibb, AstraZeneca and Revolution Medicines. A.T. is an employee of Curve Therapeutics. The other authors declare that they have no competing interests.